TY - JOUR AU - Henke, G. AU - Lindner, L. H. AU - Vogeser, M. AU - Eibl, H. J. AU - Worner, J. AU - Muller, A. C. AU - Bamberg, M. AU - Wachholz, K. AU - Belka, C. AU - Jendrossek, V. PY - 2009 DA - 2009// TI - Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy JO - Radiation Oncology (London, England) VL - 4 UR - https://doi.org/10.1186/1748-717X-4-46 DO - 10.1186/1748-717X-4-46 ID - Henke2009 ER - TY - JOUR AU - Erdlenbruch, B. AU - Jendrossek, V. AU - Gerriets, A. AU - Vetterlein, F. AU - Eibl, H. AU - Lakomek, M. PY - 1999 DA - 1999// TI - Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration JO - Cancer Chemotherapy and Pharmacology VL - 44 UR - https://doi.org/10.1007/s002800051122 DO - 10.1007/s002800051122 ID - Erdlenbruch1999 ER - TY - JOUR AU - Rubel, A. AU - Handrick, R. AU - Lindner, L. H. AU - Steiger, M. AU - Eibl, H. AU - Budach, W. AU - Belka, C. AU - Jendrossek, V. PY - 2006 DA - 2006// TI - The membrane targeted apoptosis modulators erucylphosphocholine and erucylphosphohomocholine increase the radiation response of human glioblastoma cell lines in vitro JO - Radiation Oncology (London, England) VL - 1 UR - https://doi.org/10.1186/1748-717X-1-6 DO - 10.1186/1748-717X-1-6 ID - Rubel2006 ER - TY - JOUR AU - Lawrence, T. S. AU - Blackstock, A. W. AU - McGinn, C. PY - 2003 DA - 2003// TI - The mechanism of action of radiosensitization of conventional chemotherapeutic agents JO - Semin Radiat Oncol VL - 13 UR - https://doi.org/10.1053/srao.2003.50002 DO - 10.1053/srao.2003.50002 ID - Lawrence2003 ER - TY - JOUR AU - Handrick, R. AU - Rubel, A. AU - Faltin, H. AU - Eibl, H. AU - Belka, C. AU - Jendrossek, V. PY - 2006 DA - 2006// TI - Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling JO - Radiother Oncol VL - 80 UR - https://doi.org/10.1016/j.radonc.2006.07.021 DO - 10.1016/j.radonc.2006.07.021 ID - Handrick2006 ER - TY - JOUR AU - Ruiter, G. A. AU - Zerp, S. F. AU - Bartelink, H. AU - van Blitterswijk, W. J. AU - Verheij, M. PY - 2003 DA - 2003// TI - Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway JO - Anti-cancer drugs VL - 14 UR - https://doi.org/10.1097/00001813-200302000-00011 DO - 10.1097/00001813-200302000-00011 ID - Ruiter2003 ER - TY - JOUR AU - Rudner, J. AU - Ruiner, C. E. AU - Handrick, R. AU - Eibl, H. J. AU - Belka, C. AU - Jendrossek, V. PY - 2010 DA - 2010// TI - The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation JO - Radiation Oncology (London, England) VL - 5 UR - https://doi.org/10.1186/1748-717X-5-108 DO - 10.1186/1748-717X-5-108 ID - Rudner2010 ER - TY - JOUR AU - Ruiter, G. A. AU - Zerp, S. F. AU - Bartelink, H. AU - van Blitterswijk, W. J. AU - Verheij, M. PY - 1999 DA - 1999// TI - Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis JO - Cancer Res VL - 59 ID - Ruiter1999 ER - TY - JOUR AU - Jendrossek, V. AU - Handrick, R. PY - 2003 DA - 2003// TI - Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers JO - Curr Med Chem VL - 3 ID - Jendrossek2003 ER - TY - JOUR AU - Vink, S. R. AU - van Blitterswijk, W. J. AU - Schellens, J. H. AU - Verheij, M. PY - 2007 DA - 2007// TI - Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy JO - Cancer Treatment Rev VL - 33 UR - https://doi.org/10.1016/j.ctrv.2006.12.001 DO - 10.1016/j.ctrv.2006.12.001 ID - Vink2007 ER - TY - JOUR AU - Verweij, J. AU - Planting, A. AU - van der Burg, M. AU - Stoter, G. PY - 1992 DA - 1992// TI - A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours JO - J Cancer Res Clin Oncol VL - 118 UR - https://doi.org/10.1007/BF01211805 DO - 10.1007/BF01211805 ID - Verweij1992 ER - TY - JOUR AU - Unger, C. AU - Berdel, W. AU - Hanauske, A. R. AU - Sindermann, H. AU - Engel, J. AU - Mross, K. PY - 2010 DA - 2010// TI - First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours JO - Eur J Cancer VL - 46 UR - https://doi.org/10.1016/j.ejca.2009.12.028 DO - 10.1016/j.ejca.2009.12.028 ID - Unger2010 ER - TY - JOUR AU - Van Ummersen, L. AU - Binger, K. AU - Volkman, J. AU - Marnocha, R. AU - Tutsch, K. AU - Kolesar, J. AU - Arzoomanian, R. AU - Alberti, D. AU - Wilding, G. PY - 2004 DA - 2004// TI - A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-03-0406 DO - 10.1158/1078-0432.CCR-03-0406 ID - Van Ummersen2004 ER - TY - JOUR AU - Lindner, L. H. AU - Eibl, H. AU - Hossann, M. AU - Vogeser, M. PY - 2008 DA - 2008// TI - Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard JO - J Chromatogr B Analyt Technol Biomed Life Sci VL - 869 UR - https://doi.org/10.1016/j.jchromb.2008.05.007 DO - 10.1016/j.jchromb.2008.05.007 ID - Lindner2008 ER - TY - JOUR AU - Vink, S. R. AU - Schellens, J. H. AU - Beijnen, J. H. AU - Sindermann, H. AU - Engel, J. AU - Dubbelman, R. AU - Moppi, G. AU - Hillebrand, M. J. AU - Bartelink, H. AU - Verheij, M. PY - 2006 DA - 2006// TI - Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours JO - Radiother Oncol VL - 80 UR - https://doi.org/10.1016/j.radonc.2006.07.032 DO - 10.1016/j.radonc.2006.07.032 ID - Vink2006 ER - TY - JOUR AU - Bendell, J. C. AU - Nemunaitis, J. AU - Vukelja, S. J. AU - Hagenstad, C. AU - Campos, L. T. AU - Hermann, R. C. AU - Sportelli, P. AU - Gardner, L. AU - Richards, D. A. PY - 2011 DA - 2011// TI - Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer JO - J Clinical Oncology: Official J Am Soc Clinical Oncology VL - 29 UR - https://doi.org/10.1200/JCO.2011.36.1980 DO - 10.1200/JCO.2011.36.1980 ID - Bendell2011 ER - TY - JOUR AU - Mollinedo, F. PY - 2007 DA - 2007// TI - Antitumor ether lipids: proapoptotic agents wth multiple therapeutic indications JO - Expert Opin Ther Patents VL - 17 UR - https://doi.org/10.1517/13543776.17.4.385 DO - 10.1517/13543776.17.4.385 ID - Mollinedo2007 ER - TY - JOUR AU - Stuben, G. AU - Budach, W. AU - Schick, K. H. AU - Stuschke, M. AU - Stapper, N. AU - Muller, S. AU - Feldmann, H. J. PY - 1994 DA - 1994// TI - A time-saving system for irradiations of experimental tumors JO - Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.] VL - 170 ID - Stuben1994 ER - TY - JOUR AU - Walker, A. M. AU - Suit, H. D. PY - 1983 DA - 1983// TI - Assessment of local tumor control using censored tumor response data JO - Int J Radiat Oncol Biol Phys VL - 9 UR - https://doi.org/10.1016/0360-3016(83)90300-0 DO - 10.1016/0360-3016(83)90300-0 ID - Walker1983 ER - TY - BOOK AU - Sachs, L. AU - Heddereich, J. PY - 2009 DA - 2009// TI - Angewandte Statistik. 13 PB - Springer CY - Berlin ID - Sachs2009 ER - TY - JOUR AU - Vink, S. R. AU - Schellens, J. H. AU - van Blitterswijk, W. J. AU - Verheij, M. PY - 2005 DA - 2005// TI - Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid JO - Investigational New Drugs VL - 23 UR - https://doi.org/10.1007/s10637-005-1436-0 DO - 10.1007/s10637-005-1436-0 ID - Vink2005 ER - TY - JOUR AU - de la Pena, L. AU - Burgan, W. E. AU - Carter, D. J. AU - Hollingshead, M. G. AU - Satyamitra, M. AU - Camphausen, K. AU - Tofilon, P. J. PY - 2006 DA - 2006// TI - Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells JO - Mol Cancer Ther VL - 5 UR - https://doi.org/10.1158/1535-7163.MCT-06-0091 DO - 10.1158/1535-7163.MCT-06-0091 ID - de la Pena2006 ER - TY - JOUR AU - Li, Z. AU - Tan, F. AU - Liewehr, D. J. AU - Steinberg, S. M. AU - Thiele, C. J. PY - 2010 DA - 2010// TI - In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine JO - J Natl Cancer Inst VL - 102 UR - https://doi.org/10.1093/jnci/djq125 DO - 10.1093/jnci/djq125 ID - Li2010 ER - TY - JOUR AU - Gao, Y. AU - Ishiyama, H. AU - Sun, M. AU - Brinkman, K. L. AU - Wang, X. AU - Zhu, J. AU - Mai, W. AU - Huang, Y. AU - Floryk, D. AU - Ittmann, M. PY - 2011 DA - 2011// TI - The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo JO - Radiation oncology (London, England) VL - 6 UR - https://doi.org/10.1186/1748-717X-6-39 DO - 10.1186/1748-717X-6-39 ID - Gao2011 ER - TY - JOUR AU - Marsh Rde, W. AU - Rocha Lima, C. M. AU - Levy, D. E. AU - Mitchell, E. P. AU - Rowland, K. M. AU - Benson, A. B. PY - 2007 DA - 2007// TI - A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma JO - Am J Clin Oncology VL - 30 UR - https://doi.org/10.1097/01.coc.0000251235.46149.43 DO - 10.1097/01.coc.0000251235.46149.43 ID - Marsh Rde2007 ER - TY - JOUR AU - Argiris, A. AU - Cohen, E. AU - Karrison, T. AU - Esparaz, B. AU - Mauer, A. AU - Ansari, R. AU - Wong, S. AU - Lu, Y. AU - Pins, M. AU - Dancey, J. PY - 2006 DA - 2006// TI - A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer JO - Cancer Biology & Therapy VL - 5 UR - https://doi.org/10.4161/cbt.5.7.2874 DO - 10.4161/cbt.5.7.2874 ID - Argiris2006 ER - TY - JOUR AU - Leighl, N. B. AU - Dent, S. AU - Clemons, M. AU - Vandenberg, T. A. AU - Tozer, R. AU - Warr, D. G. AU - Crump, R. M. AU - Hedley, D. AU - Pond, G. R. AU - Dancey, J. E. PY - 2008 DA - 2008// TI - A Phase 2 study of perifosine in advanced or metastatic breast cancer JO - Breast Cancer Res Treatment VL - 108 UR - https://doi.org/10.1007/s10549-007-9584-x DO - 10.1007/s10549-007-9584-x ID - Leighl2008 ER - TY - JOUR AU - Ernst, D. S. AU - Eisenhauer, E. AU - Wainman, N. AU - Davis, M. AU - Lohmann, R. AU - Baetz, T. AU - Belanger, K. AU - Smylie, M. PY - 2005 DA - 2005// TI - Phase II study of perifosine in previously untreated patients with metastatic melanoma JO - Investigational New Drugs VL - 23 UR - https://doi.org/10.1007/s10637-005-1157-4 DO - 10.1007/s10637-005-1157-4 ID - Ernst2005 ER - TY - JOUR AU - Ghobrial, I. M. AU - Roccaro, A. AU - Hong, F. AU - Weller, E. AU - Rubin, N. AU - Leduc, R. AU - Rourke, M. AU - Chuma, S. AU - Sacco, A. AU - Jia, X. PY - 2010 DA - 2010// TI - Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-1837 DO - 10.1158/1078-0432.CCR-09-1837 ID - Ghobrial2010 ER - TY - JOUR AU - Bailey, H. H. AU - Mahoney, M. R. AU - Ettinger, D. S. AU - Maples, W. J. AU - Fracasso, P. M. AU - Traynor, A. M. AU - Erlichman, C. AU - Okuno, S. H. PY - 2006 DA - 2006// TI - Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma JO - Cancer VL - 107 UR - https://doi.org/10.1002/cncr.22308 DO - 10.1002/cncr.22308 ID - Bailey2006 ER - TY - JOUR AU - Chee, K. G. AU - Longmate, J. AU - Quinn, D. I. AU - Chatta, G. AU - Pinski, J. AU - Twardowski, P. AU - Pan, C. X. AU - Cambio, A. AU - Evans, C. P. AU - Gandara, D. R. PY - 2007 DA - 2007// TI - The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial JO - Clinical Genitourinary Cancer VL - 5 UR - https://doi.org/10.3816/CGC.2007.n.031 DO - 10.3816/CGC.2007.n.031 ID - Chee2007 ER - TY - JOUR AU - Baumann, M. AU - DuBois, W. AU - Pu, A. AU - Freeman, J. AU - Suit, H. D. PY - 1992 DA - 1992// TI - Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation JO - Int J Radiat Oncol Biol Phys VL - 23 UR - https://doi.org/10.1016/0360-3016(92)90653-Y DO - 10.1016/0360-3016(92)90653-Y ID - Baumann1992 ER - TY - JOUR AU - Taghian, A. AU - DuBois, W. AU - Budach, W. AU - Baumann, M. AU - Freeman, J. AU - Suit, H. PY - 1995 DA - 1995// TI - In vivo radiation sensitivity of glioblastoma multiforme JO - Int J Radiat Oncol Biol Phys VL - 32 UR - https://doi.org/10.1016/0360-3016(94)00494-6 DO - 10.1016/0360-3016(94)00494-6 ID - Taghian1995 ER - TY - JOUR AU - Krause, M. AU - Wohlfarth, J. AU - Georgi, B. AU - Pimentel, N. AU - Dorner, D. AU - Zips, D. AU - Eicheler, W. AU - Hessel, F. AU - Short, S. C. AU - Joiner, M. C. PY - 2005 DA - 2005// TI - Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo JO - Int J Radiat Biol VL - 81 UR - https://doi.org/10.1080/09553000500491537 DO - 10.1080/09553000500491537 ID - Krause2005 ER - TY - JOUR AU - Taghian, A. AU - Budach, W. AU - Zietman, A. AU - Freeman, J. AU - Gioioso, D. AU - Ruka, W. AU - Suit, H. D. PY - 1993 DA - 1993// TI - Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice JO - Cancer Res VL - 53 ID - Taghian1993 ER - TY - JOUR AU - Short, S. AU - Mayes, C. AU - Woodcock, M. AU - Johns, H. AU - Joiner, M. C. PY - 1999 DA - 1999// TI - Low dose hypersensitivity in the T98G human glioblastoma cell line JO - Int J Radiat Biol VL - 75 UR - https://doi.org/10.1080/095530099139908 DO - 10.1080/095530099139908 ID - Short1999 ER - TY - JOUR AU - Vink, S. R. AU - Lagerwerf, S. AU - Mesman, E. AU - Schellens, J. H. AU - Begg, A. C. AU - van Blitterswijk, W. J. AU - Verheij, M. PY - 2006 DA - 2006// TI - Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-2033 DO - 10.1158/1078-0432.CCR-05-2033 ID - Vink2006 ER - TY - JOUR AU - de Vries, N. A. AU - Beijnen, J. H. AU - van Tellingen, O. PY - 2009 DA - 2009// TI - High-grade glioma mouse models and their applicability for preclinical testing JO - Cancer Treatment Rev VL - 35 UR - https://doi.org/10.1016/j.ctrv.2009.08.011 DO - 10.1016/j.ctrv.2009.08.011 ID - de Vries2009 ER - TY - JOUR AU - Haugland, H. K. AU - Nygaard, S. J. AU - Tysnes, O. B. PY - 1999 DA - 1999// TI - Combined effect of alkyl-lysophospholipid and vincristine on proliferation, migration and invasion in human glioma cell lines in vitro JO - Anticancer Res VL - 19 ID - Haugland1999 ER - TY - JOUR AU - Wang, F. Z. AU - Fei, H. R. AU - Li, X. Q. AU - Shi, R. AU - Wang, D. C. PY - 2012 DA - 2012// TI - Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells JO - Mol Cell Biochem VL - 368 UR - https://doi.org/10.1007/s11010-011-0986-z DO - 10.1007/s11010-011-0986-z ID - Wang2012 ER - TY - JOUR AU - Yosifov, D. Y. AU - Todorov, P. T. AU - Zaharieva, M. M. AU - Georgiev, K. D. AU - Pilicheva, B. A. AU - Konstantinov, S. M. AU - Berger, M. R. PY - 2011 DA - 2011// TI - Erucylphospho-N, N, N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity JO - Cancer Chemotherapy Pharmacology VL - 67 UR - https://doi.org/10.1007/s00280-010-1273-5 DO - 10.1007/s00280-010-1273-5 ID - Yosifov2011 ER - TY - JOUR AU - Potier, M. AU - Chantome, A. AU - Joulin, V. AU - Girault, A. AU - Roger, S. AU - Besson, P. AU - Jourdan, M. L. AU - LeGuennec, J. Y. AU - Bougnoux, P. AU - Vandier, C. PY - 2011 DA - 2011// TI - The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine JO - Br J Pharmacol VL - 162 UR - https://doi.org/10.1111/j.1476-5381.2010.01044.x DO - 10.1111/j.1476-5381.2010.01044.x ID - Potier2011 ER -